The mission of the Foundation for Advancement in Cancer Research is to seek out promising, scientifically-validated alternative treatment methods, to actively educate the public about them and to provide funding toward research and development of new treatments.

Below are research opportunities, current and ongoing research, and published scientific articles on an alternative cancer therapy that the Foundation feels holds much promise in the realm of non-toxic nutritional therapy for cancer (both as a standalone and integrated treatment).

Research Opportunities

Best Case Series with Poly-MVA

As our ongoing commitment to excellence in research, the Best Case Series was created to track and document the effectiveness of Poly-MVA (a dietary supplement) with cancer and quality of life. We are gathering data on patients who voluntarily elect to:

1. Refuse any conventional treatment and take only Poly-MVA
2. Take Poly-MVA with conventional treatment who have previously failed conventional treatment
3. Take Poly-MVA alone after failing conventional treatment
4. Take Poly-MVA with a conventional treatment with a very poor success rate

These patients must be monitored closely for the duration of the case study with customary laboratory and imaging data. The patient may withdraw from the study at any time and elect to use conventional treatment at any time during the study. For those patients who have financial hardship, Poly-MVA is available with assistance from Charity Research Organizations.

To date we have successfully tracked patients with several different types of cancer. You can view some of the case studies here. We are actively collecting information to assess the best possible outcome when using Poly-MVA. If you are a licensed health care provider who works with cancer patients and would like to participate in this endeavor, please contact the Research Coordinator, or Dr. Jorge Llamas, at 866-5-CANCER (866-522-6237) or via email at info@facr.org.

Looking for a practitioner who can monitor your progress while on Poly-MVA? Click here to see a listing of participating practitioners.

Quality of Life Study

The FACR, in conjunction with AMARC Enterprises, is conducting a Quality of Life Study. This research study aims to gather information on parameters such as energy, mood, efficacy and others. These will be tracked on a monthly basis in relation to the use of Poly-MVA.

To learn more about the Quality of Life Study, or to download the complete application, please click here.

Current & Ongoing Research with Poly-MVA

I. The recent and continuing research on Poly-MVA and what it can accomplish with cancer and other diseases is solid and includes the following:

• Dr. James W. Forsythe M.D., H.M.D., has completed an outcome-based investigation on various Stage IV Cancers with Poly-MVA which began in January of 2004 in Reno, Nevada. Summarized, 207 patients enlisted in the study and to date a 56 percent overall positive response rate has been presented.
• KGK Synergize Inc., an independent laboratory in Canada, examined the effects of Poly-MVA on 8 different cell lines to confirm research findings that it is effective on the following lines:
  • Skin melanoma, human (SKMel-5)
  • Liver, hepatocellular carcinoma, human (Hep G2)
  • Lung, malignant melanoma, human (Malme-3M)
  • Mammary gland, ductal carcinoma, human (MDA-MB 435)
  • Prostate, left supraclavicular lymph node carcinoma, human (LNCaP)
  • Colon, colorectal adenocarcinoma, human (HT-29)
  • Human brain, glioblastoma; astrocytoma (U87)
  • Glioblastoma (HT-80)
• Studies at a U.S. research university examined the non-toxic chemotherapeutic effects of Poly-MVA on brain and breast tumors. Separately, ischemia studies in animals demonstrated that acute, post-ischemic and prophylactic administration of Poly-MVA limits ischemic damage.
• Poly-MVA was studied independently at Calvert Laboratories, Inc. to determine its effectiveness in halting the growth of glioblastoma cells in vivo. Significantly reduced growth of the glioblastoma (50% or greater reduction in tumor size) was noted.
• The first phase (human safety) of the LAPd Ischemia Study (PUNCH: Poly-MVA Utilized as Neuroprotection against Chronic Hypertension) was completed in the Department of Neurology at Stony Brook University. The 20 patients that were administered Poly-MVA (10 mL/day) exhibited no reported SAEs (Severe Adverse Effects) or AEs (Adverse Effects) attributed to the product.
• The scientific resource booklet from Garnett-McKeen Labs shows Poly-MVA as safe and effective with cellular energy, cancer and ischemia.
• Prostate cancer and non-small cell lung cancer (NSCLC) case studies have been tracked, analyzed, written up and published by Dr. Shari Lieberman, et al.

II. The following is a recent letter concerning further research with Poly-MVA from Frank Antonawich, PhD, Senior Scientist and Clinical Research Administrator, Garnett McKeen Laboratory, Inc.:

"I would like to share with you the recent work with Poly-MVA (Palladium Lipoic Acid Complex ) and brain neoplasms. We have both "in-house" and contracted studies demonstrating the non-toxic chemotherapeutic benefits of the Palladium Lipoic Acid Complex molecules. These findings, along with numerous anecdotal and compassionate care clinical cases, has led to a formal clinical brain tumor study at Stony Brook University.

My interest in the Palladium Lipoic Acid Complex began while I was in the Department of Neurology at Stony Brook. After running numerous safety and toxicity cell culture assays, I decided to request a glioblastoma (grade IV astrocytoma) line from pathology. This previously resistant tumor started to die within 48 hours of exposure to Poly-MVA in culture. We then began to look at other lines and grades of cerebral tumors (e.g. grade II astrocytoma) with similar effectiveness. Last year I moved my laboratory to Garnett McKeen Labs and contracted KGK Synergize, Inc. to confirm our findings. Using a different in vitro chemotherapeutic assay, KGK observed similar findings with both of their cerebral neoplastic lines (astrocytoma and glioblastoma).

My Cell Physiology lab is very interested in studying the mechanism of action regarding the Palladium Lipoic Acid Complex molecules. Since neoplastic cells are metabolically challenged (i.e. elevated HIF, and other anaerobic chemicals) and function in an hypoxic (low oxygen) environment, we can take advantage of this dysfunction to selectively attack the cancer cells by providing excess electrons to the aerobic (oxygen dependent) metabolic pathway. Since the cancer cell does not have enough oxygen to quench the electrons, they are turned into radicals and destroy the cancer cell. In contrast, in the normal cells the oxygen quenches the electrons, with beneficial cellular energy being the result.

I am very excited to report that the Department of Neurology at Stony Brook (Dr. Candice Perkins) has received approval from the FDA for an Investigational New Drug (IND) application to examine the safety and effectiveness of Poly-MVA in astrocytoma and glioblastoma. This is the first FORMAL clinical brain tumor study of its kind with Poly-MVA.

Regards,

Frank Antonawich, Ph.D.
Senior Scientist and Clinical Research Administrator
Garnett McKeen Laboratory, Inc."

Published Science on Poly-MVA